[Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Record ID 32018000221
English
Original Title: Rucaparib (ovarialkarzinom) – Nutzenbewertung gemäß § 35a SGB V
Details
Project Status: Completed
Year Published: 2019
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Ovarian Neoplasms
  • Indoles
  • Maintenance Chemotherapy
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Carcinoma, Ovarian Epithelial
  • Fallopian Tube Neoplasms
  • Peritoneal Neoplasms
Keywords
  • Ovarian Neoplasms
  • Benefit Assessment
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.